Targeting Canonical Wnt-signaling Through GSK-3β in Arrhythmogenic Cardiomyopathy: Conservative or Progressive?
Open Access
- 11 October 2024
- journal article
- research article
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (1) , 121-132
Abstract
Arrhythmogenic cardiomyopathy is a primary myocardial disease and a major cause of sudden death in all populations of the world. Canonical Wnt signalling is a critical pathway controlling numerous processes including cellular differentiation, hypertrophy and development. GSK3β is a ubiquitous serine/threonine kinase, which acts downstream of Wnt to promote protein ubiquitination and proteasomal degradation. Several studies now suggest that inhibiting GSK3β can prevent and reverse key pathognomonic features of ACM in a range of experimental models. However, varying concerns are reported throughout the literature including the risk of paradoxical arrhythmias, cancer and off-target effects in upstream or downstream pathways. Clinical Relevance: In light of the start of the phase 2 TaRGET clinical trial, designed to evaluate the potential therapeutic efficacy of GSK3β inhibition in patients with arrhythmogenic cardiomyopathy, this report aims to review the advantages and disadvantages of this strategy. GraphicalKeywords
Funding Information
- British Heart Foundation (PG/23/11166)
This publication has 59 references indexed in Scilit:
- GSK3-inhibition improves maximal SERCA activity in a murine model of Arrhythmogenic cardiomyopathyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Acute Glycogen Synthase Kinase-3 Inhibition Modulates Human Cardiac ConductionJACC: Basic To Translational Science, 2022
- Premise and peril of Wnt signaling activation through GSK-3β inhibitioniScience, 2022
- A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)Pediatric Neurology, 2020
- Sodium current abnormalities and deregulation of Wnt/β-catenin signaling in iPSC-derived cardiomyocytes generated from patient with arrhythmogenic cardiomyopathy harboring compound genetic variants in plakophilin 2 geneBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- Cardiac-specific delivery by cardiac tissue-targeting peptide-expressing exosomesBiochemical and Biophysical Research Communications, 2018
- Pathogenesis of Arrhythmogenic CardiomyopathyCanadian Journal of Cardiology, 2015
- Cardiac sodium channel NaV1.5 distribution in myocytes via interacting proteins: The multiple pool modelBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
- Remodeling of the cardiac sodium channel, connexin43, and plakoglobin at the intercalated disk in patients with arrhythmogenic cardiomyopathyHeart Rhythm, 2013
- The Wnt/frizzled pathway in cardiovascular development and disease: Friend or foe?European Journal of Pharmacology, 2008